December 21, 2021
Alnylam Japan said on December 20 that it has filed a new drug application with Japanese regulatory authorities for its RNAi therapy vutrisiran for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. The company already has Onpattro (patisiran) available...read more